Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Beijing Tongren Hospital is the lead sponsor of 40 current clinical trials in our China register. 24 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Cisplatin, Pegaspargase (PEG) Asparaginase and Pembrolizumab. The most-studied condition is Myopia.

ClinicalTrials.gov trials by status

Recruiting2460%
Not yet open1230%
Active, closed38%
By invitation13%

Trials by phase

Not applicable1333%
Phase 21230%
Observational718%
Phase 438%
Phase 125%
Phase 1/225%
Phase 313%

Clinical trials sponsored by Beijing Tongren Hospital

40 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma NCT07371923 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma (DLBCL) Drugs: Pola-R-Chp, Zanubrutinib	Phase 2	Recruiting	2025-11	China
Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC NCT06725498 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drugs: Albumin-Bound Paclitaxel, Cisplatin	Phase 2	Recruiting	2024-12	China
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis NCT06510283 · ClinicalTrials.gov ↗ · Anti-N-Methyl-D-Aspartate Receptor Encephalitis	Phase 2	Recruiting	2024-12	China
Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis NCT06300203 · ClinicalTrials.gov ↗ · Seasonal Allergic Rhinitis	Phase 2	Recruiting	2024-03	China
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC NCT06102395 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Drugs: Carboplatin, Cisplatin, Docetaxel	Phase 3	Recruiting	2023-05	China
Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCC NCT07040072 · ClinicalTrials.gov ↗ · HNSCC	Phase 1	Recruiting	2025-10	China
Laser Acupuncture for Idiopathic Bell's Palsy NCT06732622 · ClinicalTrials.gov ↗ · Bell Palsy	Not applicable	Recruiting	2024-12	China
Efgartigimod in Anti-NMDA Receptor Encephalitis. NCT07822776 · ClinicalTrials.gov ↗ · Encephalitis Autoimmune	Phase 2	Recruiting	2026-06	China
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma NCT06376721 · ClinicalTrials.gov ↗ · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma Drugs: Camrelizumab, Dexamethasone, Linperlisib	Phase 1/2	Recruiting	2024-04	China
Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression NCT07323251 · ClinicalTrials.gov ↗ · Children With Myopia, Treatment, Multizone Lens Design for Myopic Defocus	Not applicable	Recruiting	2024-08	China
Real-world of AI in Diagnosing Retinal Diseases NCT05981950 · ClinicalTrials.gov ↗ · Artificial Intelligence, Retinal Diseases	Observational	Recruiting	2023-08	China
Factors Influencing Physiological Hyperopia in Children NCT06498947 · ClinicalTrials.gov ↗ · Myopia Progression	Observational	Recruiting	2024-06	China
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) NCT07525466 · ClinicalTrials.gov ↗ · Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH) Drugs: Etoposide, Golidocitinib, Methylprednisolone	Phase 1/2	Recruiting	2026-04	China
Retinal Vascular Manifestations in Patients With Common Internal Diseases on OCTA Tomography Angiography NCT05644548 · ClinicalTrials.gov ↗ · Hypertension, Diabetes Mellitus, Dyslipidemias	Observational	Recruiting	2022-03	China
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC NCT06100497 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma Drugs: Cisplatin, Paclitaxel-albumin, Pembrolizumab	Phase 2	Recruiting	2023-10	China
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma NCT07523737 · ClinicalTrials.gov ↗ · Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL)	Phase 2	Recruiting	2026-04	China
GDFT on the Postoperative Outcome in Head and Neck Cancer Surgery NCT06468852 · ClinicalTrials.gov ↗ · Postoperative Complications	Not applicable	Recruiting	2024-05	China
A Real-world Study of 650nm Low-intensity Single-wavelength Red Light for Children and Adolescents NCT05832723 · ClinicalTrials.gov ↗ · Myopia	Observational	Recruiting	2023-04	China
Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis NCT07499791 · ClinicalTrials.gov ↗ · Chronic Dacryocystitis Drug: Budesonide	Phase 2	Recruiting	2026-05	China
Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye NCT06696625 · ClinicalTrials.gov ↗ · Dry Eye Disease Drug: Sodium Hyaluronate Eye	Not applicable	Recruiting	2021-07	China
Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma NCT07355699 · ClinicalTrials.gov ↗ · Marginal Zone Lymphoma(MZL) Drug: Orelabrutinib	Phase 4	Recruiting	2025-11	China
Safety and Efficacy of Autologous Transplantation of iPSC-RPE in the Treatment of Macular Degeneration NCT05445063 · ClinicalTrials.gov ↗ · Macular Degeneration	Phase 1	Recruiting	2022-08	China
Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye Disease NCT04673643 · ClinicalTrials.gov ↗ · Dry Eye Disease	Phase 2	Recruiting	2021-07	China
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia NCT06081478 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	2022-01	China
Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children NCT07472764 · ClinicalTrials.gov ↗ · Emergence Agitation	Not applicable	Not yet open	2026-04	China
A Randomized Controlled Trial of Autostereoscopic 3D Vision Therapy for Amblyopia NCT07709832 · ClinicalTrials.gov ↗ · Amblyopia, Visual Training, Visual Functions	Not applicable	Not yet open	2026-07	China
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma NCT07554482 · ClinicalTrials.gov ↗ · Extranodal NK/T-cell Lymphoma Drugs: Gemcitabine, Oxaliplatin, Pegaspargase (PEG) Asparaginase	Phase 2	Not yet open	2026-05	China
Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps NCT07616609 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Drug: Stapokibart	Not applicable	Not yet open	2026-06	China
Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye NCT07679685 · ClinicalTrials.gov ↗ · Dry Eye Drug: Sodium Hyaluronate Eye	Phase 4	Not yet open	2026-06	China
A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps NCT06801353 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Biological Therapy, Biomarkers Drugs: Mometasone furoate, Stapokibart	Phase 4	Not yet open	2025-02	China
Evaluation of the Efficacy of Red Light in Adult Patients With High and Extreme Myopia NCT07412678 · ClinicalTrials.gov ↗ · Myopia	Not applicable	Not yet open	2026-02	China
China CRSwNP Registry Study NCT07795658 · ClinicalTrials.gov ↗ · Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	Observational	Not yet open	2026-10	China
Development of Bioluminescent Myopia Prevention and Control Instrument and Evaluation of Its Effect on Myopia NCT07208617 · ClinicalTrials.gov ↗ · Myopia	Not applicable	Not yet open	2026-02	China
Effectiveness of Digital Defocus Vision Training With Low-Concentration Atropine on the Prevention and Control of Myopia in Children: A Clinical Study NCT07724210 · ClinicalTrials.gov ↗ · Myopia, Prevention and Control	Not applicable	Not yet open	2026-08	China
"Eye" Education for Parents and Myopia Control in Children NCT06652594 · ClinicalTrials.gov ↗ · Children, Health Education, Anxiety	Not applicable	Not yet open	2024-10	China
Antagonism of Neostigmine in Continuous Infusion of Mivacurium NCT07524959 · ClinicalTrials.gov ↗ · Neuromuscular Blocking Agents	Not applicable	Not yet open	2026-05	China
The Beijing Childhood Eye Study NCT06931444 · ClinicalTrials.gov ↗ · Myopia	Observational	By invitation	2020-01	China
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma NCT07461831 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL)	Phase 2	Active, closed	2022-02	China
650nm Low-level Red-light for Myopia Control and Prevention in Children NCT05786586 · ClinicalTrials.gov ↗ · Myopia	Not applicable	Active, closed	2023-03	China
The Beijing Adult Dry Eye Cohort Study NCT06621446 · ClinicalTrials.gov ↗ · Dry Eye	Observational	Active, closed	2023-07	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Beijing Tongren Hospital trials

29 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Beijing Tongren Hospital trials

50 conditions

Myopia6 Head and Neck Squamous Cell Carcinoma3 Diffuse Large B Cell Lymphoma (DLBCL)2 Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)2Dry Eye2Dry Eye Disease2Emergence Agitation1Anti-N-Methyl-D-Aspartate Receptor Encephalitis1Seasonal Allergic Rhinitis1Amblyopia1Visual Training1Visual Functions1Visual Health1Neoadjuvant Therapy1Pembrolizumab1HNSCC1Bell Palsy1Encephalitis Autoimmune1Extranodal NK/T-cell Lymphoma1Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type1T-lymphoblastic Lymphoma1Children With Myopia1Treatment1Multizone Lens Design for Myopic Defocus1

By trial register

Register	Trials	Recruiting
Clinical trials in China	40	24

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Myopia

Sponsor	Trials
Shanghai Eye Disease Prevention and Treatment Center	13
SightGlass Vision	8
Zhongshan Ophthalmic Center, Sun Yat-sen University	7
Ruihua Wei	4
CooperVision International Limited (CVIL)	3
nthalmic	3
Beijing Visionly Plus Eye Hospital	3
Essilor International	2
Tianjin Eye Hospital	2
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical	2

Sponsors with the most current trials registered for this condition.

Questions about Beijing Tongren Hospital trials

How many clinical trials does Beijing Tongren Hospital sponsor?

Beijing Tongren Hospital is the lead sponsor of 40 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Beijing Tongren Hospital trials recruiting?

Yes. 24 of its 40 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Beijing Tongren Hospital testing?

Its current trials name 29 drugs and biologicals as interventions. The most frequent are Cisplatin (3), Pegaspargase (PEG) Asparaginase (2), Pembrolizumab (2), Sodium Hyaluronate Eye (2) and Stapokibart (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Beijing Tongren Hospital clinical trials